Health Care • Biotechnology: Pharmaceutical Preparations
$22.72 ▲ +0.19
(+0.84%)
MKT CAP: $3.83B • VOL: 5.28M
52W L $7 52W H $34
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$19
MEDIAN
$25
MEAN
$26
HIGH
$31
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TNGX TAPE
TNGX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $27.49 | $26.13 | 2025-02-14 | $20.68 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $28.63 | $26.81 | 2025-02-06 | $21.36 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $25.90 | $24.99 | 2025-01-29 | $21.81 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $23.17 | — | 2025-01-17 | $22.27 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $19.99 | $21.58 | 2025-01-09 | $20.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $27.04 | $23.63 | 2024-12-18 | $19.77 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $22.04 | $22.95 | 2024-12-04 | $21.13 | -4.3% | 48% | C |